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Summary
Background Assessment of the eﬀ ect of inﬂ uenza on populations, including risk of infection, illness if infected, illness 
severity, and consultation rates, is essential to inform future control and prevention. We aimed to compare the community 
burden and severity of seasonal and pandemic inﬂ uenza across diﬀ erent age groups and study years and gain insight 
into the extent to which traditional surveillance underestimates this burden.
Methods Using preseason and postseason serology, weekly illness reporting, and RT-PCR identiﬁ cation of inﬂ uenza 
from nasal swabs, we tracked the course of seasonal and pandemic inﬂ uenza over ﬁ ve successive cohorts (England 2006–11; 
5448 person-seasons’ follow-up). We compared burden and severity of seasonal and pandemic strains. We weighted 
analyses to the age and regional structure of England to give nationally representative estimates. We compared symptom 
proﬁ les over the ﬁ rst week of illness for diﬀ erent strains of PCR-conﬁ rmed inﬂ uenza and non-inﬂ uenza viruses using 
ordinal logistic regression with symptom severity grade as the outcome variable.
Findings Based on four-fold titre rises in strain-speciﬁ c serology, on average inﬂ uenza infected 18% (95% CI 16–22) of 
unvaccinated people each winter. Of those infected there were 69 respiratory illnesses per 100 person-inﬂ uenza-seasons 
compared with 44 per 100 in those not infected with inﬂ uenza. The age-adjusted attributable rate of illness if infected was 
23 illnesses per 100 person-seasons (13–34), suggesting most inﬂ uenza infections are asymptomatic. 25% (18–35) of all 
people with serologically conﬁ rmed infections had PCR-conﬁ rmed disease. 17% (10–26) of people with PCR-conﬁ rmed 
inﬂ uenza had medically attended illness. These ﬁ gures did not diﬀ er signiﬁ cantly when comparing pandemic with 
seasonal inﬂ uenza. Of PCR-conﬁ rmed cases, people infected with the 2009 pandemic strain had markedly less severe 
symptoms than those infected with seasonal H3N2.
Interpretation Seasonal inﬂ uenza and the 2009 pandemic strain were characterised by similar high rates of mainly 
asymptomatic infection with most symptomatic cases self-managing without medical consultation. In the community 
the 2009 pandemic strain caused milder symptoms than seasonal H3N2.
Funding Medical Research Council and the Wellcome Trust.
Copyright © Hayward et al. Open Access article distributed under the terms of CC BY.
Introduction
Inﬂ uenza causes roughly 250 000–500 000 deaths 
worldwide each year.1 In the 20th century there were three 
inﬂ uenza pandemics for which there are varying mortality 
estimates: 1918 A/H1N1 at least 20–40 million excess 
deaths, 1957 A/H2N2 about 4 million excess deaths, and 
1968 A/H3N2 about 2 million excess deaths.2–4 In 2009 a 
new pandemic virus,5 inﬂ uenza A(H1N1)pdm09, emerged 
in Mexico6 and spread globally over 2009–10, causing an 
estimated 200 000 respiratory deaths and 83 000 cardio-
vascular deaths during the ﬁ rst 12 months of circulation.7 
WHO declared an end to the pandemic on Aug 10, 2010.8 
However, a further pandemic wave occurred in some 
European and other countries outside North America9 in 
2010–11 with reports of excess deaths in, for example, 
England.10
Internationally, inﬂ uenza activity surveillance provides 
real-time information to inform prevention and control 
policy.11 Surveillance focuses on cases seeking medical 
attention: the so-called tip of the iceberg of infection. 
Underestimation of the number of community cases leads 
to overestimates of severity.12,13 Heightened concern during 
a pandemic can change patient consultation thresholds 
and clinician recording and investigation behaviour, thus 
distorting surveillance information.14 Information on the 
community burden of inﬂ uenza is key to informing 
control,15 but is not routinely collected. For example, 
inﬂ uenza transmission models, which are widely used to 
consider the eﬃ  cacy and cost-eﬀ ectiveness of vaccines, 
antivirals, and non-pharmaceutical counter measures, 
depend on valid epidemiological estimates of the 
community occurrence of disease. The available data for 
periods of seasonal inﬂ uenza are largely derived historically 
from household cohort studies of families with children in 
communities in the USA between 1948 and 1981,16–19 and a 
more recent study from rural Vietnam.20 There have also 
been some cohort studies reporting on the 2009 pandemic 
from Hong Kong, southeast Asia, and Mali21–25 as well as 
Lancet Respir Med 2014; 
2: 445–54
Published Online
March 17, 2014
http://dx.doi.org/10.1016/
S2213-2600(14)70034-7
See Comment page 430
*Joint senior author
UCL Research Department 
of Infection and Population 
Health (A C Hayward MD, 
E B Fragaszy MSc, A Copas PhD, 
G Harvey MPH, J Kovar PhD, 
M S C Lim PhD, 
E R C Millett MSc, 
F Tabassum PhD, F B Wurie BSc, 
Prof A M Johnson MD), and 
UCL Department of Primary 
Care and Population Health 
(I Nazareth PhD), University 
College London, London, UK; 
Department of Infectious 
Disease Epidemiology, 
London School of Hygiene & 
Tropical Medicine, London, UK 
(E B Fragaszy, W J Edmunds 
PhD, E R C Millett); Respiratory 
Virus Unit 
(A Bermingham PhD, 
M Zambon PhD), and 
Respiratory Diseases 
Department (R Pebody MBChB, 
J M Watson FRCP), Public 
Health England, Colindale, UK; 
Weatherall Institute of 
Molecular Medicine, 
University of Oxford, Oxford, 
UK (L Wang PhD, 
N Goonetilleke PhD, 
A McMichael PhD); 
Department of Microbiology 
and Immunology, University 
of North Carolina at Chapel 
Hill, Chapel Hill, NC, USA 
(N Goonetilleke); Department 
of Infectious Disease 
Epidemiology, Imperial 
College London, London, UK 
(N Ferguson DPhil); Centre 
for Population Health, Burnet 
Institute, Melbourne, VIC, 
Australia (M S C Lim); and 
Health Protection and 
Influenza Research Group, 
Division of Epidemiology and 
Public Health, University of 
Nottingham, Nottingham, UK 
(J S Nguyen-Van-Tam DM)
Articles
446 www.thelancet.com/respiratory   Vol 2   June 2014
Correspondence to:
Dr Andrew C Hayward, UCL 
Research Department of 
Infection and Population Health, 
University College London, 
Hampstead Campus, Rowland 
Hill Street, London NW3 2PF, UK
a.hayward@ucl.ac.uk
several cross-sectional serosurveys from this period.26 
Case-ascertained household transmission studies can 
estimate the secondary attack proportion and eﬀ ects of 
interventions within households; however, they are not 
designed to estimate community burden of inﬂ uenza 
infection and disease.27,28 The Flu Watch study is the ﬁ rst 
national community cohort study of inﬂ uenza occurrence 
enrolling households with and without children, with the 
additional beneﬁ t of modern molecular diagnostic 
techniques.
We aimed to compare the community burden and 
severity of seasonal and pandemic inﬂ uenza across 
diﬀ erent age groups and study years and gain insight into 
the extent to which traditional surveillance underestimates 
this burden. Our speciﬁ c objectives were to measure the 
proportion of the population infected each season, the 
proportion of those infected who developed symptomatic 
disease attributable to inﬂ uenza, the proportion who had 
detectable nasal shedding of inﬂ uenza virus, the symptoms 
among those with conﬁ rmed inﬂ uenza, and the proportion 
who were medically attended. During the pandemic we 
also aimed to measure the development of type-speciﬁ c 
immunity to the pandemic strain.
Methods
Participants 
We did a household-level community cohort study of acute 
respiratory illness and inﬂ uenza infection, recruiting 
households across England (appendix). We followed up 
successive cohorts over the 2006–07, 2007–08, and 2008–09 
periods of seasonal inﬂ uenza circulation, and the ﬁ rst 
(spring and summer 2009), second (autumn and winter 
2009), and third (winter 2010–11) waves of the pandemic. 
Households were recruited annually through written 
invitation sent to a random sample of people registered 
with 146 volunteer general practices as well as inviting 
previous participants (in 2008–11). In England, most of the 
population is registered with a general practice.29 At 
baseline (October–December) and follow-up visits 
(May–July) of each year we collected blood samples for 
serological testing (willingness to provide samples was a 
condition of participation in adults, voluntary in children 
aged 5–15 years, and not requested in children younger 
than 5 years). Follow-up samples from spring 2009 acted 
as baseline specimens for individuals who continued to 
participate through the 2009–10 pandemic.
Participants gave written informed consent (proxy 
consent for children). The protocol was approved by the 
Oxford MultiCentre Research Ethics Committee. 
(06/Q1604/103).
Procedures 
We collected demographic and medical history data at 
baseline and self-reported vaccination status at baseline 
and end of follow-up. Admissions to hospital and deaths 
during follow-up were recorded with the end of season 
follow-up questionnaire completed by the lead householder, 
with deaths among participants also being reported to the 
study by participating practices and directly by families. We 
minimised recall bias of illness through weekly telephone 
or online surveys to record any “cough, cold, sore throat, or 
ﬂ u-like illness” among household members. In addition to 
weekly surveys, participants were asked to complete 
detailed daily symptom diaries for the duration of any acute 
respiratory illness, including daily temperature 
measurement and reporting of several symptoms: feeling 
feverish, headache, having muscle aches, cough, sore 
throat, runny nose, blocked nose, and sneezing. Symptoms 
were allocated a numerical score on the basis of severity 
(0=absent, 1=mild, 2=moderate, 3=severe or for fever 
<37·8°C=0, 37·8–38·9°C=1, 39·0–39·9°C=2, ≥40°C=3). 
Review of participants’ primary-care records was used to 
measure consultation behaviour in practices where a 
research nurse was available to extract the data. We asked 
participants to submit, by mail, nasal swabs on day 2 of any 
illness. These swabs were transported in viral transport 
medium and screened by RT-PCR for inﬂ uenza A 
(subtypes H1, H3), inﬂ uenza B, inﬂ uenza A(H1N1)pdm09 
(from 2009 onwards), and a panel of other respiratory 
viruses including respiratory syncytial virus, rhinovirus, 
coronavirus, adenovirus, human metapneumovirus, and 
parainﬂ uenza virus with methods described elsewhere.30,31 
We measured serum antibody titres against circulating 
inﬂ uenza strains (appendix) in baseline and follow-up 
samples with haemagglutination inhibition assay using 
standard methods.32,33
Outcomes 
Key outcomes of interest were infection with inﬂ uenza, 
deﬁ ned as a four-fold titre rise in serum samples of 
unvaccinated individuals (but not in vaccinated individuals 
since both vaccination and natural infection lead to titre 
rises); occurrence of any acute respiratory illness (self-
reported “cough, cold, sore throat, or ﬂ u-like illness”); 
occurrence of inﬂ uenza-like illness, deﬁ ned according to 
the US Centers for Disease Control and Prevention (CDC) 
deﬁ nition of fever (temperature ≥37·8°C) and a cough or a 
sore throat in the absence of a known cause other than 
inﬂ uenza;34 occurrence of PCR-conﬁ rmed inﬂ uenza; 
symptom severity over the ﬁ rst week of illness in PCR-
conﬁ rmed cases; and consultation with primary care. 
During the pandemic additional outcomes included 
monitoring the development of immunity (deﬁ ned as 
antibody titre to inﬂ uenza A H1N1 pdm2009 of ≥32). In 
this analysis key predictors of interest are age, study year, 
and circulating strain of inﬂ uenza. The study size was 
chosen to give accurate annual estimates of infection and 
disease rates such that a sample size of 800 per year would 
allow a 25% risk of infection to be estimated within 
95% CIs of 22–25 and a 10% risk of inﬂ uenza-like illness 
within 95% CIs of 8–12. The study was expanded in the 
pandemic to provide accurate real-time measures of 
inﬂ uenza-like illness rates recruiting as many participants 
as was practically possible.
See Online for appendix
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Statistical analysis 
Analyses were done in STATA version 12. Analyses of 
serological data were restricted to those with serological 
samples available (no children younger than 5 years had 
serological specimens). We weighted analyses to the age 
and regional structure of England to give nationally 
representative estimates. In this weighting, children 
younger than 15 years were considered as a single group, 
so measures of age-adjusted population rates of infection 
(but not of PCR-conﬁ rmed disease or illness) apply the 
rates in the 5–15 year age group to the 0–15 population. We 
did not weight on ethnic origin or social deprivation 
because there was no evidence of a strong association with 
infection or disease rates (data not shown) and small or 
zero numbers in some groups would have led to instability 
of weighted measures.
Participants were assumed not to have a respiratory 
illness in weeks with missing illness status reports. After 
excluding illnesses where PCR identiﬁ ed a non-inﬂ uenza 
virus we plotted rates of respiratory illness, inﬂ uenza-like 
illness, and PCR-conﬁ rmed inﬂ uenza (per 100 000 person-
weeks). We estimated the percentage of the population 
infected each season by calculating age and season-speciﬁ c 
rates of serological infection and PCR-conﬁ rmed disease 
per 100 person-seasons. A person-season was deﬁ ned as 
the time from the ﬁ rst PCR isolation of inﬂ uenza in the 
cohort to the last isolation in any given season, rates 
therefore accounted for diﬀ erential follow-up time during 
periods of inﬂ uenza circulation. We did not undertake 
follow-up blood samples for serological testing for 
participants recruited before the ﬁ rst (spring/summer) 
pandemic wave until after the second (winter) wave had 
ﬁ nished because we had not predicted separate summer 
and winter pandemic waves. Methods to derive infection 
rates in the ﬁ rst wave are described in the appendix.
We estimated the percentage of serological infections 
leading to illness by two independent methods. First, we 
calculated age-adjusted attributable rates of illness due to 
infection (subtracting rates of respiratory illness in non-
seroconverters from those in seroconverters).35 Sensitivity 
November, 2006, to 
March, 2007
November, 2007, to 
March, 2008
November, 2008, to 
March, 2009
May, 2009, to 
September, 2009
October, 2009, to 
February, 2010
November, 2010, to 
March, 2011
GP practices/households/people 42/243/602 43/310/779 37/309/729 41/332/797 127/1460/3552 51/361/901
Age group, years
0–4 (6%) 38 (6%) 42 (5 %) 37 (5%) 36 (5%) 179 (5 %) 45 (5%)
5–15 (11%) 87 (15%) 110 (14%) 99 (14%) 109 (14%) 501 (14%) 131 (15%)
16–44 (42%) 151 (25%) 258 (33%) 172 (24%) 192 (24%) 848 (24%) 206 (23%)
45–64 (25%) 203 (34%) 272 (35%) 267 (37%) 293 (37%) 1225 (35%) 344 (38%)
≥65 (16%) 123 (20%) 97 (13%) 154 (21%) 167 (21%) 799 (23%) 175 (19%)
Sex
Male (49%) 281 (47%) 366 (47%) 340 (47%) 377 (47%) 1740 (49%) 455 (51%)
Female (51%) 321 (53%) 413 (53%) 389 (53%) 420 (53%) 1812 (51%) 446 (50%)
Region
North (28%) 99 (17%) 89 (11%) 100 (14%) 106 (13%) 320 (9%) 115 (13%)
West Midlands (11%) 42 (7%) 96 (12%) 46 (6%) 53 (7%) 179 (5%) 53 (6%)
East and east Midlands (20%) 122 (20%) 120 (15%) 124 (17%) 118 (15%) 1456 (41%) 321 (36%)
London (15%) 28 (5%) 77 (10%) 26 (4%) 28 (4%) 270 (8%) 65 (7%)
Southeast (16%) 100 (17%) 117 (15%) 107 (15%) 155 (20%) 319 (9%) 110 (12%)
Southwest (10%) 211 (35%) 280 (36%) 326 (45%) 337 (42%) 1008 (28%) 237 (26%)
Vaccine
Vaccinated 115 (19%) 130 (17%) 169 (23%) 0 157 (4%) 186 (21%)
Unvaccinated 462 (77%) 632 (81%) 527 (72%) 797 (100%) 3159 (89%) 715 (79%)
Unknown 25 (4%) 17 (2%) 33 (5%) 0 236 (7%) 0
IMD quintile
1 (20%) 37 (6%) 39 (5%) 28 (4%) 18 (2%) 98 (3%) 29 (3%)
2 (20%) 88 (15%) 126 (16%) 91 (13%) 62 (8%) 310 (9%) 82 (9%)
3 (20%) 164 (27%) 235 (30%) 238 (33%) 146 (18%) 915 (26%) 221 (25%)
4 (20%) 162 (27%) 250 (32%) 187 (26%) 146 (18%) 938 (26%) 280 (31%)
5 (20%) 151 (25%) 129 (17%) 185 (25%) 425 (53%) 1291 (56%) 289 (32%)
Ethnic origin
White (75%) 557 (98%) 733 (95%) 666 (99%) 730 (99%) 3306 (98%) 846 (98%)
Non-white (25%) 5 (2%) 35 (5%) 6 (1%) 7 (1%) 78 (2%) 19 (2%)
Percentages given alongside the categories are the national distributions. Data are n (%). IMD=Index of Multiple Deprivation.
 Table 1: Baseline characteristics
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analyses inﬂ ated these adjusted attributable rates to 
account for the recorded level of under-reporting (based on 
the proportion of expected weekly illness status reports 
received during periods of inﬂ uenza circulation). Second, 
we measured the proportion of unvaccinated sero-
converters with PCR-conﬁ rmed inﬂ uenza.
We compared symptom proﬁ les (an ordered categorical 
variable) over the ﬁ rst week of illness for diﬀ erent strains 
of PCR-conﬁ rmed inﬂ uenza and non-inﬂ uenza viruses 
using ordinal logistic regression with symptom severity 
grade as the outcome variable, adjusting for age group and 
strain type and accounting for repeated measures in 
individuals using robust standard errors (Stata ologit 
commands with cluster option).
Role of the funding source 
The sponsors had no role in study design, collection 
analysis, interpretation of data, or writing of the report. 
ACH, EBF, and ERCM had access to the raw data. The 
corresponding author had full access to all data and ﬁ nal 
responsibility to submit for publication.
Results
Roughly 10% of invited households agreed to participate 
(appendix). Table 1 presents the comparison of unweighted 
cohort demographics with those of the England population 
showing good geographical spread but under-
representation of young adults; people living in socially 
deprived areas, north England, west Midlands, and 
London; and people of non-white ethnic origin.
Person follow-up time (118 158 person-weeks, 
5448 person-seasons), illness-status reports (102 300: 
86·6% of follow-up weeks), nasal swab submissions (2941; 
88·3% of 3332 illnesses recorded during periods of 
inﬂ uenza circulation), and inﬂ uenza virus detection 
results are given in the appendix. There were 3295 paired 
sera (81% of eligible adults and 27% of eligible children 
aged 5–15 years, in whom blood tests were optional). Of 
these 2737 (83 %) were in unvaccinated individuals.
The highest rates of inﬂ uenza-like illness and PCR-
conﬁ rmed inﬂ uenza were during the epidemic of H3N2 in 
2008–09 before the pandemic and in the 2010–11 third 
pandemic wave. Compared with other seasons, illness 
rates in the ﬁ rst pandemic wave were low (ﬁ gure 1).
The dominant circulating strain was inﬂ uenza A H3N2 
in 2006–07, seasonal A H1N1 in 2007–08, A H3N2 in 
2008–09, and A(H1N1)pdm09 in 2009–10 and 2010–11. 
Inﬂ uenza B circulated in 2007–08 and 2008–09 when it 
peaked after the main inﬂ uenza A outbreak. In 2010–11 the 
inﬂ uenza B peak coincided with the third wave 
of A(H1N1)pdm09. On average, based on rates per 
100 person-seasons, PCR-conﬁ rmed inﬂ uenza was 
identiﬁ ed in 4% (95% CI 3–5) of the cohort each winter: 
3% (2–5) during prepandemic seasons and 5% (4–6) 
during pandemic winter seasons. Highest rates were in 
the third pandemic wave when 9% (6–13) had PCR-
conﬁ rmed disease (6% inﬂ uenza A and 3% inﬂ uenza B) 
and in the 2008–09 season when 6% (4–10) had PCR-
conﬁ rmed disease (5% inﬂ uenza A and 2% inﬂ uenza B). 
In all seasons most PCR-conﬁ rmed cases were inﬂ uenza A, 
although inﬂ uenza B was important in 2007–08, 2008–09, 
and 2010–11.
Risk of PCR-conﬁ rmed disease tended to decrease with 
increasing age (ﬁ gure 2, appendix). For inﬂ uenza A this 
age dependence was most apparent during the H3N2 
epidemic of 2008–09 and the 2009–10 second wave of the 
H1N1 pandemic when children had signiﬁ cantly higher 
rates of PCR-conﬁ rmed disease and serological infection 
with inﬂ uenza A than older adults (appendix). For 
inﬂ uenza B, children had signiﬁ cantly higher rates of 
PCR-conﬁ rmed disease than adults in 2008–09 and 2010–
11 seasons (appendix). The 2010–11 third wave of the H1N1 
pandemic was unusual in having markedly higher rates of 
inﬂ uenza A in young adults than any other season. PCR-
conﬁ rmed inﬂ uenza was very rare in people older than 
65 years in all seasons.
On average, based on rates per 100 person-seasons, 
inﬂ uenza infected 18% (95% CI 16–22) of the unvaccinated 
population each winter season: 19% (15–24) during 
prepandemic seasons and 18% (14–22) during the 
pandemic. The highest infection rate (27%, 22–34; 
24% inﬂ uenza A, 2% inﬂ uenza B) was in the season 
Figure 1: Rates of illness or PCR-conﬁ rmed inﬂ uenza standardised by age and region
Rates of acute respiratory illness, inﬂ uenza-like illness, and PCR-conﬁ rmed inﬂ uenza per 100 000 person-weeks. Excludes illnesses known to be due to non-inﬂ uenza viruses.
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preceding the pandemic (2008–09) and then in the 2010–11 
third pandemic wave (22%, 17–28; 18 inﬂ uenza A, 5% 
inﬂ uenza B).
Infection rates were typically highest in children aged 
5–15 years (not measured in younger children) and 
decreased with age (ﬁ gure 2, appendix). This age-
dependence was most apparent during the 2009 ﬁ rst 
pandemic wave when children aged 5–15 years was the 
only age group with measurable risk of infection: 
26% (0–58). Age dependence of inﬂ uenza A was also 
strong during the 2009–10 second wave of the pandemic 
when children had signiﬁ cantly higher rates of serological 
infection with inﬂ uenza A than older adults (appendix). 
The 2010–11 third pandemic wave was the only season 
when young adults aged 16–44 years had the highest risk of 
infection: 34% (26–46). During periods of seasonal 
inﬂ uenza A age dependence was strongest during the 
H3N2 epidemic of 2008–09 (appendix). Children also had 
signiﬁ cantly higher rates of inﬂ uenza B infection than 
older adults in 2008–09 (appendix).
Most infections were asymptomatic. 192 respiratory 
illnesses including 70 inﬂ uenza-like illnesses were reported 
from 327 participants with serological evidence of infection 
over 280 person-seasons of follow-up (69 respiratory 
illnesses, 25 inﬂ uenza-like illnesses per 100 person-
seasons). There were 623 respiratory illnesses including 
95 inﬂ uenza-like illnesses reported from 1742 participants 
with no serological evidence of infection over 1423 person-
seasons of follow-up (44 respiratory illnesses, seven 
inﬂ uenza-like illnesses per 100 person-seasons). The rate of 
respiratory illness attributable to inﬂ uenza (age-adjusted 
incidence rate diﬀ erence)35 was 23 respiratory illnesses 
Figure 2: Rates of seasonal and pandemic inﬂ uenza A infection and PCR-conﬁ rmed disease
Rates of infection established through seroconversion (four-fold titre rises in unvaccinated individuals) and rates of disease established through PCR-conﬁ rmation per 
100 person-seasons (95% CIs).
0
5
10
15
20
25
30
35
40
45
Ra
te
 (%
)
Seasonal influenza A
Seasonal 2006–07
Pandemic influenza A
Pandemic ﬁrst wave, summer 2009
0
5
10
15
20
25
30
35
40
45
Ra
te
 (%
)
Seasonal 2007–08 Pandemic second wave, 2009–10
0 to 4 5 to 15 16 to 44 45 to 64 65+
0
5
10
15
20
25
30
35
40
45
Ra
te
 (%
)
Age group (years)
Seasonal 2008–09
0 to 4 5 to 15 16 to 44 45 to 64 65+
Age group (years)
Pandemic third wave, 2010–11
Infection (serology)
Disease (PCR)
Articles
450 www.thelancet.com/respiratory   Vol 2   June 2014
(95% CI 13–34) including 18 inﬂ uenza-like illnesses 
per 100 person-seasons (95% CI 12–24). There was in-
suﬃ  cient power to test the hypothesis that the asymptomatic 
proportion varied by age or strain type. Sensitivity analyses 
adjusting for the fact that 85% of illness status reports were 
returned during periods of inﬂ uenza circulation gave 
estimates of the rate of respiratory illness or inﬂ uenza-like 
illness attributable to infection of 27 respiratory illnesses 
and 21 inﬂ uenza-like illnesses per 100 person-seasons, 
respectively. These estimates of infections leading to 
disease are similar to the 25% (18–35) of people with 
serological infections who had PCR-conﬁ rmed inﬂ uenza 
from nasal swabs. PCR-conﬁ rmation levels seemed to be 
lower in adults aged 65 years or older (9%, 95% CI 1–60) 
and for inﬂ uenza B infections (5%, 1–28), although this 
was not statistically signiﬁ cant.
Only a minority of people with PCR-conﬁ rmed inﬂ uenza 
had fever with a temperature greater than 37·8°C and so 
met the CDC deﬁ nition of inﬂ uenza-like illness (110/238; 
46%, 95% CI 40–53). Symptoms of A(H1N1)pdm09 were 
milder than those of H3N2 (appendix). Detailed daily 
symptom diaries were available on 567 participants with 
PCR-conﬁ rmed respiratory illnesses (102 A[H1N1]pdm09, 
35 H3N2, ten H1N1, 35 inﬂ uenza B, 385 non-inﬂ uenza 
viruses). Symptoms of inﬂ uenza A(H1N1)pdm09 were 
milder than those of H3N2 for feeling feverish, headache, 
muscle ache, runny nose, sneezing, and blocked nose 
(table 2). Symptoms of A(H1N1)pdm09 were signiﬁ cantly 
more severe than those of non-inﬂ uenza viruses for fever, 
feeling feverish, muscle aches, and cough, but signiﬁ cantly 
less severe than non-inﬂ uenza viruses for runny nose, 
sneezing, and blocked nose (table 2). Children were 
signiﬁ cantly more likely than adults to have fever (table 2).
Most people with PCR-conﬁ rmed inﬂ uenza did not 
consult and among those who did, inﬂ uenza or inﬂ uenza-
Fever Feverish Headache Muscle ache Sore throat Cough Runny nose Sneeze Blocked nose
A(H1N1)pdm09* 
(n=102)
1 1 1 1 1 1 1 1 1
H3N2
(n=35)
1·09
(0·61–1·95); 
0·774
2·22
(1·33–3·71); 
0·002
2·72
(1·60–4·63); 
<0·001
4·15
(2·36–7·27); 
<0·001
1·51
(0·90–2·54); 
0·118
1·34
(0·82–2·18); 
0·245
3·18
(2·12–4·77); 
<0·001
2·95
(1·88–4·62); 
<0·001
2·39
(1·46–3·93); 
0·001
H1N1
(n=10)
0·27
(0·09–0·87); 
0·027
0·59
(0·28–1·25); 
0·172
1·53
(1·83–2·81); 
0·173
1·23
(0·49–3·08); 
0·653
2·29
(1·13–4·60); 
0·020
0·85
(0·47–1·54); 
0·584
2·26
(1·24–4·10); 
0·007
1·74
(1·00–3·02); 
0·05
1·76
(0·96–3·23); 
0·068
Inﬂ uenza B 
(n=35)
1·56
(0·87–2·80); 
0·134
1·94
(1·08–3·47); 
0·026
1·27
(0·72–2·25); 
0·411
1·79
(0·91–3·52); 
0·094
1·32
(0·73–2·37); 
0·694
0·69
(0·35–1·37); 
0·290
1·01
(0·59–1·72); 
0·972
1·0
(0·56–1·78); 
0·990
2·02
(1·14–3·58); 
0·017
Non-inﬂ uenza 
(n=385)
0·34
(0·22–0·53); 
<0·001
0·51
(0·36–0·72); 
<0·001
1·02
(0·74–1·41); 
0·905
0·66
(0·44–0·98); 
0·040
1·07
(0·76–1·50); 
0·694
0·56
(0·40–0·77); 
<0·001
1·95
(1·45–2·62); 
<0·001
1·50
(1·11–2·05); 
0·009
1·93
(1·14–3·58); 
0·017
0–15 years* 
(n=189)
1 1 1 1 1 1 1 1 1
16–44 years 
(n=147)
0·25
(0·15–0·41); 
<0·001
0·95
(0·66–1·39); 
0·803
1·32
(0·95–1·85); 
0·098
1·48
(0·98–2·22); 
0·06
1·60
(1·16–2·20); 
0·005
0·68
(0·50–0·94); 
0·019
0·91
(0·68–1·20); 
0·0503
1·28
(0·96–1·70); 
0·09
1·18
(0·85–1·63); 
0·323
45–64 years 
(n=195)
0·31
(0·20–0·50); 
<0·001
1·55
(1·11–2·18); 
0·010
1·22
(0·89–1·67); 
0·219
1·75
(1·18–2·59); 
0·005
1·35
(0·99–1·87); 
0·056
0·81
(0·60–1·08); 
1·045
0·82
(0·63–1·07); 
0·148
1·15
(0·87–1·52); 
0·324
0·97
(0·71–1·32); 
0·826
≥65 years (n=70) 0·135
(0·07–0·28); 
<0·001
1·09
(0·67–1·78); 
0·726
0·97
(0·64–1·47); 
0·888
1·67
(0·94–2·97); 
0·08
1·12
(0·75–1·68); 
0·569
1·22
(0·84–1·76); 
0·0294
1·08
(0·74–1·58); 
0·678
2·10
(1·36–2·96); 
<0·001
0·88
(0·54–1·42); 
0·595
Data are adjusted OR (95% CI); p value (across the categories of the symptom severity scale, assuming proportional odds). Numbers in the left-hand column refer to the number 
of PCR-conﬁ rmed cases across all years with information on daily symptoms. ORs are mutually adjusted for age and strain type. OR=odds ratio. *Baseline group for comparisons.
Table 2: Comparative symptom severity for diﬀ erent strains of inﬂ uenza and non-inﬂ uenza viruses and diﬀ erent age groups
Figure 3: Number of expected events in a surveillance practice serving a population of 10 000 people
Data for a typical inﬂ uenza season.
8172 registered patients
who are not infected
1371 registered patients with
asymptomatic infection
379 PCR-conﬁrmable registered patients
who do not consult their family doctor
54 PCR-conﬁrmable medically attended patients who
are not reported as inﬂuenza by surveillance practice
24 medically attended patients reported as 
PCR-conﬁrmed by surveillance practice
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like illness was rarely recorded in medical notes. Medical 
record review of 93 PCR-conﬁ rmed inﬂ uenza cases across 
all seasons and of 459 episodes of inﬂ uenza-like illness 
showed that 16 of 93 people with PCR-conﬁ rmed inﬂ uenza 
(17%, 10–26) and 96 of 459 people with episodes of 
inﬂ uenza-like illness (21%, 17–25) consulted their family 
doctor. Of the 96 patients consulting with inﬂ uenza-like 
illness only eight (8%, 4–16) had inﬂ uenza or inﬂ uenza-
like illness recorded in their medical record. Of the people 
with respiratory illness, those younger than 5 years were 
most likely to have a medical consultation (appendix).
Of 133 PCR-conﬁ rmed cases of inﬂ uenza, with data 
available from end of season surveys, there was one 
admission to hospital potentially attributable to inﬂ uenza 
(febrile convulsions in a child younger than 5 years within 
2 weeks of a positive swab for inﬂ uenza A H1N1 pdm2009). 
There were no deaths among these 133 PCR-conﬁ rmed 
cases. This single admission gives a maximum estimated 
hospitalisation rate of 0·75% (95% CI 0·02–4·19). Of 
226 seroconverters to inﬂ uenza, with data available from 
end of season surveys, there were two admissions to 
hospital that were potentially attributable to inﬂ uenza: one 
in a young adult with a four-fold titre rise to inﬂ uenza A 
H1N1 pdm2009 admitted with a chest infection in the 
winter of 2010–11 and one in an individual aged 45–64 years 
with a four-fold rise in titre to inﬂ uenza B admitted with 
pneumonia during the winter of 2010–11. These two 
admissions give a maximum estimated hospitalisation 
rate for serological infection of 0·88% (95% CI 0·11–3·19). 
This compares with three respiratory hospitalisations in 
1730 participants who did not have a four-fold titre rise 
(0·17%, 95% CI 0·04–0·51). There were two respiratory 
deaths in the cohort, both of which occurred in vaccinated 
participants older than 65 years during the 2008–09 winter 
season; one was partly attributable to chest infection and 
the other was attributable to pneumonia. It is not possible 
to infer whether or not inﬂ uenza contributed because 
there were no nasal swab samples and post mortem serum 
samples were not sought.
Primary-care-based surveillance greatly under estimated 
the extent of infection and illness in the community 
(ﬁ gure 3). Under ascertainment was lower during the 
summer wave of the pandemic. The rate of PCR-conﬁ rmed 
inﬂ uenza across all winter seasons was on average 
22-times higher (95% CI 17–28) than rates of PCR-
conﬁ rmed disease from the Royal College of General 
Practitioners Sentinel Inﬂ uenza-Like Illness/Virological 
Surveillance Scheme.36 During the pandemic summer 
wave the rate was only three-times higher.
In children aged 5–15 years, protective antibodies were 
mainly acquired as a result of natural infection over the 
ﬁ rst and second pandemic wave, in young adults 
(16–44 years) protective antibody levels increased mainly as 
a result of natural infection in the second and third wave, 
in people older than 45 years protective antibodies were 
mainly acquired as a result of vaccination during the 
second and third waves (ﬁ gure 4).
Discussion
Flu Watch is one of the largest and most comprehensive 
studies of its type since the 1980s (panel).19 Through 
providing reliable information on the epidemiology and 
burden of seasonal and pandemic inﬂ uenza we hope to 
inform future decisions on seasonal disease control and 
pandemic planning. For example, better measures of 
community disease burden will increase the validity of 
population models that are widely used to infer the 
eﬃ  cacy and cost-eﬀ ectiveness of countermeasures such 
as use of antivirals, vaccines, and behavioural 
Figure 4: Immune proﬁ les to inﬂ uenza A(H1N1)pdm09 before each 
inﬂ uenza season.
Proﬁ les before ﬁ rst wave (no vaccine; A), after second wave and before third 
wave (B), and after third wave (C). HI=haemagglutinin inhibition.
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interventions. On average inﬂ uenza infected 18% of 
unvaccinated people each winter. Up to three-quarters 
of infections were asymptomatic and about a quarter 
of infections had PCR-conﬁ rmed disease. 17% of people 
with PCR-conﬁ rmed disease had medically 
attended illness. These data did not vary signiﬁ cantly 
when comparing pandemic with seasonal inﬂ uenza. 
People infected with the 2009 pandemic strain had 
markedly less severe symptoms than those infected 
with seasonal H3N2.
The study covers six inﬂ uenza seasons, including 
seasonal and pandemic periods, but the variable nature of 
inﬂ uenza means that we cannot exclude substantially 
more severe periods of both seasonal and pandemic 
inﬂ uenza in the future. The study was limited by the 
diﬃ  culty in obtaining a fully representative sample 
because, although selection was random, acceptance rates 
were low. Weighted analyses ensured results represented 
the age and regional structure of the country. Weighted 
analyses of overall population rates of infection (but not 
illness or disease) assume the level of infection recorded in 
children younger than ﬁ ve years were similar to those in 
those aged 5–16 years. However, because children younger 
than 5 years represent only about 6% of the UK population 
the lack of serological analysis in this group will not have 
made a major diﬀ erence to overall reported rates. Our 
estimates of infection in people older than 65 years are 
limited to unvaccinated individuals because we cannot 
reliably infer infection from titre rises in vaccinated people.
Diﬀ erences in volunteers such as propensity to consult if 
ill and uptake of interventions might aﬀ ect ﬁ ndings. 
Participants were generally highly diligent at completing 
weekly illness reports and submitting nasal swabs during 
illness (>85% completion). That the proportion of 
infections judged symptomatic was very similar using two 
independent methods (proportion of seroconverters PCR-
conﬁ rmed and attributable-rate of respiratory illness in 
seroconverters compared with non-seroconverters)35 
suggests that the low proportion with PCR-conﬁ rmed 
disease is not simply a matter of low test sensitivity. Nasal 
swabs have similar sensitivity to the gold-standard 
nasopharyngeal aspirates.37,38 Self-taken swabs have similar 
sensitivity to those taken by health-care workers.39 The 
extent of postal delay is not associated with likelihood of 
PCR positivity for inﬂ uenza.40 After adjusting for time 
from symptom onset to swab date, a recent comparison 
showed similar levels of viral detection and viral load in 
primary-care samples from patients with inﬂ uenza-like 
illness to those in postally submitted samples from 
patients consulting the National Pandemic Flu Service.41 
Because of the high level of completion of weekly illness 
status reports, adjusting our attributable rates for the 
recorded level of under-reporting made minimal diﬀ erence 
to our conclusions on the proportion of infections leading 
to illness. The attributable-rate method might 
underestimate the proportion of infections leading to 
illness if having inﬂ uenza reduces the risk of other 
respiratory infections through viral interference,42 but we 
did not identify any evidence of this in our data.
Reported cases of inﬂ uenza represent the tip of a large 
clinical and subclinical iceberg that is mainly invisible to 
routine surveillance systems (ﬁ gure 3). Surveillance does 
not aim to capture the totality of community cases, but low 
ascertainment means that changes in consultation and 
reporting behaviour during periods of increased concern 
can make interpretation of trends highly problematic. It is 
also likely that propensity to consult if ill might vary by 
country, making international comparisons diﬃ  cult. Our 
ﬁ ndings show this during the summer wave of the 
pandemic, where comparison of disease rates with 
national surveillance suggest a much higher proportion of 
cases were identiﬁ ed with surveillance than at other times. 
This greater identiﬁ cation probably represents an increase 
in propensity for people to consult and be reported during 
periods of increased national concern; however, because 
only two conﬁ rmed cases were identiﬁ ed in the study 
Panel: Research in context
Systematic review
We searched published work to address four key questions relevant to our study: what 
proportion of the population have inﬂ uenza infection each inﬂ uenza season, what 
proportion of infections lead to illness, what are the symptom proﬁ les and severity of these 
illnesses, and what proportion of these illnesses lead to consultation? We reviewed 
historical community cohort studies of respiratory infections such as the Tecumseh study,18 
the methods of which were adapted for the Flu Watch study. These studies are summarised 
elsewhere.19 We also reviewed ﬁ ndings from more recent cohort studies using similar 
designs.20–23 We then did three separate systematic literature searches in Embase, Global 
Health, and Medline databases (up to Aug 13, 2013) to identify community-level cohort 
studies of inﬂ uenza with PCR or serological conﬁ rmation (search terms in appendix).
To identify work relevant to establishing population-level inﬂ uenza infection rates, we 
reviewed a recent review and meta-analysis of age-speciﬁ c cumulative incidence for the 
2009 inﬂ uenza pandemic.26 We also searched published work for community-level cohort 
studies of inﬂ uenza that collected paired sera (search terms in appendix). Studies were 
included in this review if they were community-level cohorts but excluded if they only 
focused on subsections of the population.
To add to the work identiﬁ ed above, we did a further two systematic literature searches in 
the same databases to identify relevant community-level prospective cohort studies that 
had PCR conﬁ rmation of inﬂ uenza illnesses (search terms in appendix). Studies were 
included if they were community-level cohorts with prospective follow-up of respiratory 
illnesses with swabbing for PCR conﬁ rmation of inﬂ uenza. Studies were excluded if they 
only focused on subsections of the population or if they only did PCRs on a subset of 
illnesses (ie, only consulting illnesses or only those meeting a case deﬁ nition which would 
exclude less severe inﬂ uenza).
Interpretation
Our rates of infection and disease were similar to those found in historical cohort studies 
and in more recent, mostly pandemic, studies.18–20 Our ﬁ nding that a high proportion of 
infections were asymptomatic was consistent with other research.35 Inﬂ uenza A H3N2 has 
previously been reported as causing more severe symptoms than Inﬂ uenza A H1N1.35 
Others have also reported that a high proportion of people with inﬂ uenza-like illness do not 
seek medical attention.14
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during this summer period we cannot test this directly. 
From a population perspective there was little diﬀ erence in 
burden of disease in the 2009 pandemic compared with 
seasonal inﬂ uenza periods. Both seasonal and pandemic 
infections were common, especially in children, but most 
infection was asymptomatic and most symptomatic cases 
did not consult. The symptoms associated with 2009 
pandemic inﬂ uenza were substantially milder than those 
of seasonal H3N2. The completeness of return of weekly 
illness status reports did not alter during the pandemic, 
suggesting that change in reporting to the study was not a 
source of bias (appendix). Hospitalisation and death rates 
were very low with insuﬃ  cient events to establish if this 
varied by strain type.
After the high attack rates during the 2009–10 pandemic, 
WHO advised that the virus had largely run its course.8 
Despite this, a further wave of A(H1N1)pdm09 infection 
was noted across Europe in 2010–11.9 In England this wave 
was associated with an upwards age shift in infected people 
admitted to hospital (median age 35 years during the 
2010–11 winter compared with 20 years over the 2009–10 
pandemic period) and pressure on intensive care.43 We did 
not identify any evidence of increased symptom severity in 
the third wave, but there was a marked increase in the 
number of cases in young adults. This upwards age shift is 
probably explained by the fact that before this third wave, 
protective antibody titres were present in about three-
quarters of children, but only about a third of working-age 
adults. However, it remains unclear why young adults were 
not more aﬀ ected during earlier waves. The higher 
numbers of deaths and admissions noted nationally during 
the pandemic third wave were therefore probably due to 
increased numbers of cases in young adults rather than, as 
reported by others, increased severity.44 The occurrence of a 
third wave in the pandemic reinforces the value of investing 
in vaccine development even if vaccines are unlikely to be 
available suﬃ  ciently early to alter the course of early waves.
The proportion of serologically conﬁ rmed infections that 
are asymptomatic is an often neglected variable, which is 
an important component of severity. Our ﬁ nding that only 
23% (95% CI 13–34) of infections are symptomatic is lower 
than is sometimes assumed, but is consistent with 
ﬁ ndings from other studies of seasonal inﬂ uenza35 and 
human challenge studies.45 Measurement of the proportion 
of serologically conﬁ rmed infections that are asymptomatic 
should be an early priority for any emerging infection of 
pandemic potential. This provides an additional index of 
severity  complementing population level data on 
admission to hospital and deaths. Our study was limited 
by our inability to identify virus shedding during 
asymptomatic infection because this would have needed 
frequent regular nasal swabbing throughout follow-up. 
Comparison of symptom proﬁ les in community cases of 
an emerging infection with those noted with other viruses 
can also provide important information on severity, 
complementing population level data on numbers of 
admissions to hospital and deaths.
Application of consistent methods across periods of 
seasonal and pandemic inﬂ uenza has allowed assessment 
of the 2009 pandemic in context. Although A(H1N1)
pdm09 infected most children and a high proportion of 
unvaccinated adults of all ages over three pandemic waves, 
infection and disease rates were similar to or lower than 
prepandemic periods. Symptoms due to infection with the 
2009 pandemic strain were milder than those with 
seasonal inﬂ uenza strains. Our ﬁ ndings are consistent 
with the very low case-fatality rates recorded during the 
pandemic. Whereas overall, pandemic illnesses were mild 
there was a shift in the age distribution of deaths leading to 
an increase in years of life lost during the 2009 pandemic 
compared with some seasonal periods.7 Despite its mild 
nature, the 2009 pandemic caused enormous international 
concern, expense, and disruption. We need to prepare for 
how to respond to both mild and severe pandemics. To do 
this we need more reﬁ ned assessments of severity, 
including community studies to guide control measures 
early in the course of a pandemic and inform a 
proportionate response.
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